181 related articles for article (PubMed ID: 36806647)
1. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis.
Parthasarathy V; Cravero K; Xu L; Deng J; Sun Z; Engle SM; Sims JT; Okragly AJ; Kwatra SG
J Am Acad Dermatol; 2023 May; 88(5):1101-1109. PubMed ID: 36806647
[TBL] [Abstract][Full Text] [Related]
2. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans.
Sutaria N; Alphonse MP; Marani M; Parthasarathy V; Deng J; Wongvibulsin S; Williams K; Roh YS; Choi J; Bordeaux Z; Pritchard T; Dillen C; Semenov YR; Kwatra MM; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
J Invest Dermatol; 2022 May; 142(5):1300-1308.e3. PubMed ID: 34717952
[TBL] [Abstract][Full Text] [Related]
3. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
Chu L; Wang LK; Wu Y; Yang H; Wang W; Lu Q; Deng H
Actas Dermosifiliogr; 2022 Mar; 113(3):244-253. PubMed ID: 35282859
[TBL] [Abstract][Full Text] [Related]
4. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
Chu L; Wang L; Wu Y; Yang H; Wang W; Lu Q; Deng H
Actas Dermosifiliogr; 2022 Mar; 113(3):T244-T253. PubMed ID: 35331446
[TBL] [Abstract][Full Text] [Related]
5. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
6. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis.
Parthasarathy V; Cravero K; Deng J; Sun Z; Engle SM; Auxier AN; Hahn N; Sims JT; Okragly AJ; Alphonse MP; Kwatra SG
Front Med (Lausanne); 2022; 9():1011142. PubMed ID: 36561717
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and economic burden of prurigo nodularis.
Whang KA; Le TK; Khanna R; Williams KA; Roh YS; Sutaria N; Choi J; Gabriel S; Chavda R; Semenov Y; Kwatra SG
J Am Acad Dermatol; 2022 Mar; 86(3):573-580. PubMed ID: 34058278
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
11. Prurigo Nodularis: Review and Emerging Treatments.
Leis M; Fleming P; Lynde CW
Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
[TBL] [Abstract][Full Text] [Related]
12. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus.
Vaidya DC; Schwartz RA
Acta Dermatovenerol Croat; 2008; 16(1):38-44. PubMed ID: 18358109
[TBL] [Abstract][Full Text] [Related]
13. Ethnic differences and comorbidities of 909 prurigo nodularis patients.
Boozalis E; Tang O; Patel S; Semenov YR; Pereira MP; Stander S; Kang S; Kwatra SG
J Am Acad Dermatol; 2018 Oct; 79(4):714-719.e3. PubMed ID: 29733939
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
[No Abstract] [Full Text] [Related]
15. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
16. [Psychosomatic aspects of prurigo nodularis].
Schneider G; Hockmann J; Stumpf A
Hautarzt; 2014 Aug; 65(8):704-8. PubMed ID: 25113329
[TBL] [Abstract][Full Text] [Related]
17. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
Zhang Z; Li S; Wang Y; Zhao J
An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis.
Marani M; Madan V; Le TK; Deng J; Lee KK; Ma EZ; Kwatra SG
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397136
[TBL] [Abstract][Full Text] [Related]
19. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.
Hashimoto T; Nattkemper LA; Kim HS; Kursewicz CD; Fowler E; Shah SM; Nanda S; Fayne RA; Paolini JF; Romanelli P; Yosipovitch G
Exp Dermatol; 2021 Jun; 30(6):804-810. PubMed ID: 33428793
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis.
Sutaria N; Marani M; Choi J; Roh YS; Parthasarathy V; Deng J; Bordeaux ZA; Taylor MT; Lee KK; Pritchard T; Alajmi A; Adawi W; Semenov YR; Alphonse MP; Kwatra SG
J Dermatol Sci; 2022 Feb; 105(2):130-136. PubMed ID: 35151532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
